Evidence map›Paper›PMID 36382763›Full record

ReviewArchives of endocrinology and metabolism2022

Male osteoporosis.

Leonardo Bandeira, Barbara C Silva, John P Bilezikian

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of Vitamin B₆ in Testosterone Synthesis.The world journal of men's health · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Bone Material Properties in Male Idiopathic Osteoporosis.Calcified tissue international · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Leonardo BandeiraUniversidade Federal de São Paulo, São Paulo, SP, Brasil.
Barbara C SilvaDepartamento de Medicina, Centro Universitário de Belo Horizonte (UNI-BH), Belo Horizonte, MG, Brasil.
John P BilezikianDivision of Endocrinology, Metabolic Bone Diseases Unit, College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Columbia University · USFleury S.A. (Brazil) · BRSanta Casa Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis receive adequate treatment. Up to half of the cases of male osteoporosis have a secondary cause, the most common being hypogonadism, excessive alcohol consumption, and chronic use of glucocorticoids. The International Society for Clinical Densitometry (ISCD) recommends using the female database for the diagnosis of osteoporosis by DXA (T-score ≤ -2.5 in men over 50 years old). In addition, osteoporosis can also be diagnosed independently of the BMD if a fragility fracture is present, or if there is a high risk of fractures by FRAX. Treatment is similar to postmenopausal osteoporosis, because the data regarding changes in bone density track closely to those in women. Data concerning fracture risk reduction are not as certain because the clinical trials have included fewer subjects for shorter period of time. In men with symptomatic hypogonadism, testosterone replacement, if indicated, can improve BMD.

Indexed as

HypogonadismOsteoporosisOsteoporosis, PostmenopausalOsteoporotic FracturesAbsorptiometry, PhotonBone DensityFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorshypogonadismmaleOsteoporosistestosterone

Identifiers

PMID36382763
PMCPMC10118818
OpenAlexW4309363583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.